Robert Kuo-Kuang Lee

Dr. Robert Kuo-Kuang Lee


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SLSheng-Hsiang Li
Sheng-Hsiang Li
YHYuh-Ming Hwu
Yuh-Ming Hwu
CLChung-Hao Lu
Chung-Hao Lu
HCHsiao-Ho Chang
Hsiao-Ho Chang
CHCheng-En Hsieh
Cheng-En Hsieh
RLRobert Kuo-Kuang Lee
Robert Kuo-Kuang Lee
This study was conducted to investigate the effect of the vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) on revascularization, survival, and oocyte quality of cryopreserved, subcutaneously-transplanted mouse ovarian tissue. Autologous subcutaneous transplantation of vitrified-thawed mouse ovarian tissues treated with (experimental group) or without (control group) VEGF and FGF2 was performed. After transplantation to the inguinal region for two or three weeks, graft survival, angiogenesis, follicle development, and oocyte quality were examined after gonadotropin administration. VEGF coupled with FGF2 (VEGF/FGF2) promoted revascularization and significantly increased the survival rate of subcutaneously-transplanted cryopreserved ovarian tissues compared with untreated controls. The two growth factors did not show long-term effects on the ovarian grafts. In contrast to the untreated ovarian grafts, active folliculogenesis was revealed as the number of follicles at various stages and of mature oocytes in antral follicles after gonadotropin administration were remarkably higher in the VEGF/FGF2-treated groups. Although the fertilization rate was similar between the VEGF/FGF2 and control groups, the oocyte quality was much better in the VEGF/FGF2-treated grafts as demonstrated by the higher ratio of blastocyst development. Introducing angiogenic factors, such as VEGF and FGF2, may be a promising strategy to improve revascularization, survival, and oocyte quality of cryopreserved, subcutaneously-transplanted mouse ovarian tissue.

30 January 2018 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
RLRobert Kuo-Kuang Lee
Robert Kuo-Kuang Lee
HTHuan-Chin Tseng
Huan-Chin Tseng
YHYuh-Ming Hwu
Yuh-Ming Hwu
CFChi-Chen Fan
Chi-Chen Fan
MLMing-Huei Lin
Ming-Huei Lin
SLSheng-Hsiang Li
Sheng-Hsiang Li
Cystatin C (CST3), a cysteine protease inhibitor in seminal plasma, is expressed in animal uteri. However, its expression in the human female reproductive tract and its effect on human sperm capacitation are unclear. The cellular localization of CST3 was observed using immunohistochemistry. The binding of CST3 to sperm was examined using immunocytochemistry. Sperm motility parameters were analyzed using computer-assisted sperm analysis. Sperm capacitation was evaluated by analyzing cholesterol content, protein tyrosine phosphorylation levels, and the acrosome reaction. Immunohistochemical staining demonstrated that CST3 is prominently expressed in the female reproductive tract, including the epithelial lining and cervix and endometrium fluids, particularly at times near ovulation. It can bind to human sperm on the post-acrosomal head region and the mid and principal piece of the tail. CST3 enhances sperm motility and inhibits the signal initiating sperm capacitation, i.e., efflux of cholesterol from the sperm plasma membrane and a late sperm capacitation event, i.e., the increase in the sperm protein tyrosine phosphorylation. The suppressive trend on sperm acrosome reaction further supports CST3’s ability to inhibit sperm capacitation. These findings suggest that cervical CST3 may prevent precocious capacitation and acrosome reaction, thus preserving sperm fertilizing ability before it reaches the fallopian tube. Additionally, CST3 may help sperm enter the upper reproductive tract by enhancing sperm motility.

Verified
Journal Article
Open access
PDF file
SLSheng-Hsiang Li
Sheng-Hsiang Li
YHYuh-Ming Hwu
Yuh-Ming Hwu
CLChung-Hao Lu
Chung-Hao Lu
MLMing-Huei Lin
Ming-Huei Lin
LYling yu Yeh
ling yu Yeh
RLRobert Kuo-Kuang Lee
Robert Kuo-Kuang Lee
SERPINE2 (serpin peptidase inhibitor, clade E, member 2), predominantly expressed in the seminal vesicle, can inhibit murine sperm capacitation, suggesting its role as a sperm decapacitation factor (DF). A characteristic of DF is its ability to reverse the capacitation process. Here, we investigated whether SERPINE2 can reversibly modulate sperm capacitation. Immunocytochemical staining revealed that SERPINE2 was bound onto both capacitated and uncapacitated sperm. It reversed the increase in BSA-induced sperm protein tyrosine phosphorylation levels. The effective dose and incubation time were found to be >0.1 mg/mL and >60 min, respectively. Calcium ion levels in the capacitated sperm were reduced to a level similar to that in uncapacitated sperm after 90 min of incubation with SERPINE2. In addition, the acrosome reaction of capacitated sperm was inhibited after 90 min of incubation with SERPINE2. Oviductal sperm was readily induced to undergo the acrosome reaction using the A23187 ionophore; however, the acrosome reaction was significantly reduced after incubation with SERPINE2 for 60 and 120 min. These findings suggested that SERPINE2 prevented as well as reversed sperm capacitation in vitro. It also prevented the acrosome reaction in in vivo-capacitated sperm isolated from the oviduct. Thus, SERPINE2 could reversibly modulate murine sperm capacitation.

Verified
Journal Article
Open access
PDF file
LYling yu Yeh
ling yu Yeh
RLRobert Kuo-Kuang Lee
Robert Kuo-Kuang Lee
MLMing-Huei Lin
Ming-Huei Lin
CHChih-Hung Huang
Chih-Hung Huang
SLSheng-Hsiang Li
Sheng-Hsiang Li
Few studies have examined the correlation between sperm miRNA levels and clinical outcomes of intracytoplasmic sperm injection (ICSI). In this study, we aimed to assess the correlation of sperm miR-34b, miR-34c, miR-122, and miR-429 levels with ICSI outcomes in men with teratozoospermia and asthenozoospermia. TaqMan microRNA quantitative polymerase chain reaction was used to evaluate the relative expression of miRNAs in sperm. The relative miRNA levels quantified using a comparative method found that the four miRNAs were not associated with fertilization rate and early embryo development. However, revels of miR-34b and miR-34c in teratozoospermia sperm of the live birth group were significantly higher than those in the non-live birth group. Receiver operating characteristic curve analysis revealed that the optimal cut-off delta cycle threshold values of miR-34b and miR-34c were 8.630 and 7.883, respectively. Statistical analysis found that the levels of miR-34b and the miR-34c in teratozoospermic and asthenozoospermic sperm above the thresholds were not associated with the fertilization rate and the high-quality embryo rate above 50%; however, they were more likely to exhibit higher implantation, pregnancy, and live birth rates. miR-34b and miR-34c were significantly associated with ICSI clinical outcomes in male factor infertility, especially teratozoospermia. Further validation is required before it becomes a clinically valid reference indicator.

29 October 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
HLHung-Shih Lin
Hung-Shih Lin
RLRobert Kuo-Kuang Lee
Robert Kuo-Kuang Lee
TYTsung-Hsien Yang
Tsung-Hsien Yang
Hsu-Wei FangHsu-Wei Fang
Hsu-Wei Fang
SLSheng-Hsiang Li
Sheng-Hsiang Li
Quiescin Q6 sulfhydryl oxidase 1 (QSOX1) catalyzes the oxidation of the sulfhydryl group to disulfide bond and is widely expressed in various tissues. This study focuses on investigating QSOX1′s spatiotemporal and cellular protein expression profile of the pregnant uterus, placenta, and developing embryo during mouse pregnancy. Immunohistochemical staining was used to reveal the localization of QSOX1 protein, and HistoQuest was applied to quantify protein levels. The expression level of QSOX1 in the decidua and muscle cells of the pregnant uterus fluctuated dramatically during pregnancy. QSOX1 was ubiquitously expressed in the labyrinth, junction zone, and chorionic plate in the placenta. The quantitative analysis found that this protein was highly expressed in the spinal cord, lens, midbrain, cerebellum, medulla oblongata, and tooth of mouse embryos, followed by the heart, intercostal muscle, diaphragm, intermediate zone, extrinsic ocular muscle, spine, pons, epidermis, tongue, ganglion, vomeronasal organ, thoracic vertebrae, and thymus. Interestingly, QSOX1 was also markedly expressed in olfactory system tissues. This comprehensive spatiotemporal study of QSOX1 protein expression will provide a basis for further investigations of the QSOX1 physiological function in the pregnant uterus, placenta, and developing embryo.